Q-omics provides the consensus-scored GPR75-ASB3 profile across patient tissues and cancer cell-line models. GPR75-ASB3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, GPR75-ASB3 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, GPR75-ASB3 RNA expression shows 17,323 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where GPR75-ASB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR75-ASB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR75-ASB3 survival associations across molecular data types. GPR75-ASB3 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR75-ASB3 RNA expression–survival associations across cancer types. High GPR75-ASB3 expression shows unfavorable associations in UVM, CESC and BRCA, but favorable associations in UCS, READ and MESO. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for GPR75-ASB3 RNA expression.
This table summarizes GPR75-ASB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPR75-ASB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR75-ASB3 shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in STAD, CHOL and LIHC. The THCA box plot shows higher GPR75-ASB3 RNA expression in normal versus tumor tissue (log2 FC = −0.093, t-test p < 0.001).
This table shows molecular features associated with GPR75-ASB3 in patient tissues and cancer cell lines. In patient samples, GPR75-ASB3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR75-ASB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OESOPHAGUS.
